This review article examined multiple classes of antiarrhythmic agents—including conventional Class I-IV antiarrhythmics, late sodium current inhibitors, potassium channel enhancers, ryanodine receptor stabilizers, gap junction modulators, atrial-selective agents, and the peptide BPC 157—and their proposed cytoprotective mechanisms in managing cardiac arrhythmias. The authors synthesized evidence suggesting these various drug classes may provide cardioprotection through different cellular pathways, though the review does not present new experimental data comparing efficacy. This is a **review article** synthesizing existing literature rather than original human clinical or experimental research.